{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143"}]}],"title":"Any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"107"}]}],"title":"Grade ≥3 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"57"}]}],"title":"Serious TEAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"}],"units":"Participants"}],"description":"An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that did not necessarily have to have a causal relationship with treatment. A TEAE was an adverse event with an onset that began or worsened on or after the first dose date and until 30 days after the last dose date, or start of a new anticancer therapy/procedure, whichever came earlier. TEAE assessments also included those per the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Grade ≥3 AEs and serious TEAEs.\n\nAEs were graded using CTCAE version 4 and according to the following: Grade 1 = mild AE, Grade 2 = Moderate AE, Grade 3 = a severe AE, Grade 4 = life-threatening AE, and Grade 5 = death due to AE. For events not listed in the CTCAE criteria, the same grading was used.","groups":[{"description":"Participants received loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurred first.","id":"OG000","title":"Loncastuximab Tesirine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All-treated population - all participants who received at least 1 dose of treatment.","reportingStatus":"POSTED","timeFrame":"Up to 599 days","title":"Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}